ReviewTherapeutic advances in musculoskeletal disease2019
Balancing benefits and risks in the era of biologics.
Review in Therapeutic advances in musculoskeletal disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pain management of hip osteoarthritis with corticosteroids vs injection therapies: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2025Pooled it
- Machine Learning-Based Development of Gadolinium Binding Peptides.NMR in biomedicine · 2026Article
- Optimisation of in vitro assays for accurate risk assessment of T-cell responses to biologics with potential immune liabilities.Archives of toxicology · 2026Article
- Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune Diseases.Inflammation · 2026Article
- Manganese oxide nanozyme-loaded CO-releasing halloysite nanotubes for remodeling colonic immune, microbiota, and intestinal barrier homeostasis with concurrent pain relief in ulcerative colitis.Bioactive materials · 2026Article
- Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics.Biomedicines · 2026Review
- A novel peptide-compound conjugate alleviates endotoxin-induced inflammation via NF-κB/MAPK modulation.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Machine learning-based development of Gadolinium binding peptides.bioRxiv : the preprint server for biology · 2025Article
- LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis.Journal of the Endocrine Society · 2025Article
- Hepatitis C Direct-Acting Antivirals in the Immunosuppressed Host: Mechanisms, Interactions, and Clinical Outcomes.Viruses · 2025Review
- The Therapeutic Potential of Extracellular Vesicles in Psoriasis Treatment: Mechanisms, Applications, and Prospects.International journal of molecular sciences · 2025Review
- Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Assessment of antipsoriatic potential of novel pemetrexed disodium-loaded transdermal patches in an imiquimod-induced mouse model.Immunologic research · 2025Article
- BeyondChemical reviews · 2025Review
- Article
- Article
- Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity.Current allergy and asthma reports · 2024Review
- Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.PloS one · 2024Article
- Unraveling the Relationship Between Osteoporosis, Treatment Modalities, and Oral Health: A Comprehensive Review.Cureus · 2023Review
- Maximizing the benefits of using biosimilars in Egypt.Journal of pharmaceutical policy and practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologics are substances synthetized from biological sources used in the prevention and treatment of several diseases. Rheumatologists have many years of experience with biologics for the treatment of immune-mediated diseases and osteoporosis. Randomized clinical trials and postmarketing studies have demonstrated that treatment with biologics can result, albeit infrequently, in serious adverse events. To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.